The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion

Brain and Development

Volumn 32, Issue 6, 2010, Pages 435-439

  Tanuma, Naoyuki ^a,h   Miyata, Rie ^b,h   Kumada, Satoko ^c   Kubota, Masaya ^d   Takanashi, Jun ichi ^e   Okumura, Akihisa ^f   Hamano, Shin ichiro ^g   Hayashi, Masaharu ^h  

^a Tokyo Metropolitan Fuchu Medical Center for the Disabled   (Japan)

^b Department of Pediatrics   (Japan)

^c TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e KAMEDA MEDICAL CENTER   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

^g SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^h TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Acute encephalopathy; Axonal damage; Tau protein

Indexed keywords

NEURON SPECIFIC ENOLASE; TAU PROTEIN;

ACUTE ENCEPHALOPATHY WITH BIPHASIC SEIZURES AND LATE REDUCED DIFFUSION; ARTICLE; AXONAL INJURY; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; INFANT; MALE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; WHITE MATTER;

ACUTE DISEASE; ADOLESCENT; AGE FACTORS; AXONS; BRAIN; BRAIN DISEASES; CHILD; CHILD, PRESCHOOL; DIFFUSION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; INFANT; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; PHOSPHOPYRUVATE HYDRATASE; SEIZURES; TAU PROTEINS; TIME FACTORS;

EID: 77952547846     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.07.004     Document Type: Article

References (21)

1. Ost M., Nylen K., Csajbok L., Ohrfelt A.O., Tullberg M., Wikkelso C., et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006, 67:1600-1604.
2. Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66:852-856.
3. Rostasy K., Withut E., Pohl D., Lange P., Ciesielcyk B., Diem R., et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005, 20:822-825.
4. Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005, 4:32-41.
5. Terzi M., Birinci A., Cetinkaya E., Onar M.K. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007, 115:325-330.
6. Takanashi J, Oba H, Barkovich AJ, Tada H, Tanabe Y, Yamanouchi H, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006;66:1304-9 [discussion 1291].
7. Takanashi J., Tsuji M., Amemiya K., Tada H., Barkovich A.J. Mild influenza encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2007, 256:86-89.
8. LoPresti P., Szuchet S., Papasozomenos S.C., Zinkowski R.P., Binder L.I. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci USA 1995, 92:10369-10373.
9. Gorath M., Stahnke T., Mronga T., Goldbaum O., Richter-Landsberg C. Developmental changes of tau protein and mRNA in cultured rat brain oligodendrocytes. Glia 2001, 36:89-101.
10. Gordon D., Kidd G.J., Smith R. Antisense suppression of tau in cultured rat oligodendrocytes inhibits process formation. J Neurosci Res 2008, 86:2591-2601.
11. Parnetti L., Palumbo B., Cardinali L., Loreti F., Chionne F., Cecchetti R., et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett 1995, 183:43-45.
12. Palumbo B., Siepi D., Sabalich I., Tranfaglia C., Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?. Funct Neurol 2008, 23:93-96.
13. Mizuguchi M., Yamanouchi H., Ichiyama T., Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007, 115:45-56.
14. Takanashi J., Tada H., Terada H., Barkovich A.J. Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. AJNR Am J Neuroradiol 2008, 30:132-135.
15. Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008.
16. Werner P., Pitt D., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180.
17. Smith K.J. Axonal protection in multiple sclerosis - a particular need during remyelination?. Brain 2006, 129:3147-3149.
18. Black J.A., Liu S., Hains B.C., Saab C.Y., Waxman S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006, 129:3196-3208.
19. Black J.A., Waxman S.G. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci 2008, 274:57-63.
20. Chin R.F., Neville B.G., Peckham C., Wade A., Bedford H., Scott R.C. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008, 7:696-703.
21. Sugai K. Treatment of convulsive status epilepticus in infants and young children in Japan. Acta Neurol Scand 2007, 115:62-70.